



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/EP2011/056158

(22) International Filing Date:

18 April 2011 (18.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10161632.4 30 April 2010 (30.04.2010) EP

(71) Applicant (for all designated States except US): **CELL-ZOME LIMITED** [GB/GB]; Chesterford Research Park, Little Chesterford, Cambridge CB10 1XL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HARRISON, Richard, John** [GB/GB]; 30 Chalmers Road, Cambridge CB1 3SX (GB). **OXENFORD, Sally** [GB/GB]; 6 Havercroft Close, St Albans, Herts, UK AL3 4LD (GB). **HOBSON, Andrew** [GB/GB]; 30 Rustat Avenue, Cambridge CB1 3PF (GB). **RAMSDEN, Nigel** [GB/GB]; Sparrows Lodge, Green Lane, Fowlmere, Royston, Herts SG8 7QP (GB). **MILLER, Warren** [GB/GB]; 21 Grebe Court, Cambridge, UK CB58FR (GB).

(74) Agent: **BÜCHEL, Edwin**; Isenbruck Bösl Hörschler LLP Patentanwälte, Eastsite One, Seckenheimer Landstraße 4, 68163 Mannheim (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRAZOLE COMPOUNDS AS JAK INHIBITORS



(57) Abstract: The present invention relates to compounds of formula (I), wherein R¹, R², R^{1a}, R^{1b} have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

PYRAZOLE COMPOUNDS AS JAK INHIBITORS

5 The present invention relates to a novel class of kinase inhibitors, including pharmaceutically acceptable salts, prodrugs and metabolites thereof, which are useful for modulating protein kinase activity for modulating cellular activities such as signal transduction, proliferation, and cytokine secretion. More specifically the invention provides compounds which inhibit, regulate and/or modulate kinase activity, in particular JAK3 activity, and signal transduction pathways relating to cellular activities as mentioned above. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds, for example for the treatment or prevention of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease and processes for preparing said compounds.

10 Kinases catalyze the phosphorylation of proteins, lipids, sugars, nucleosides and other cellular metabolites and play key roles in all aspects of eukaryotic cell physiology. Especially, protein kinases and lipid kinases participate in the signaling events which control the activation, growth, differentiation and survival of cells in response to extracellular mediators or stimuli such as growth factors, cytokines or chemokines. In general, protein kinases are classified in two groups, those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine and/or threonine residues. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor (EGFR) and cytosolic non-receptor kinases such as Janus kinases (JAK).

25 Inappropriately high protein kinase activity is involved in many diseases including cancer, metabolic diseases, autoimmune or inflammatory disorders. This effect can be caused either directly or indirectly by the failure of control mechanisms due to mutation, overexpression or inappropriate activation of the enzyme. In all of these instances, selective inhibition of the kinase is expected to have a beneficial effect.

30 One group of kinases that has become a recent focus of drug discovery is the Janus kinase (JAK) family of non-receptor tyrosine kinases. In mammals, the family has four members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2). Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain. The JAK proteins bind to cytokine receptors through their amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains. After the binding of cytokines to their receptors, JAKs are activated and phosphorylate the receptors,

thereby creating docking sites for signalling molecules, especially for members of the signal transducer and activator of transcription (Stat) family (Yamaoka et al., 2004. The Janus kinases (Jaks). Genome Biology 5(12): 253).

- 5 In mammals, JAK1, JAK2 and TYK2 are ubiquitously expressed. By contrast, the expression of JAK3 is predominantly in hematopoietic cells and it is highly regulated with cell development and activation (Musso et al., 1995. 181(4):1425-31).

10 The study of JAK-deficient cell lines and gene-targeted mice has revealed the essential, nonredundant functions of JAKs in cytokine signalling. JAK1 knockout mice display a perinatal lethal phenotype, probably related to the neurological effects that prevent them from sucking (Rodig et al., 1998. Cell 93(3):373-83). Deletion of the JAK2 gene results in embryonic lethality at embryonic day 12.5 as a result of a defect in erythropoiesis (Neubauer et al., 1998. Cell 93(3):397-409). Interestingly, JAK3 deficiency was first identified in
15 humans with autosomal recessive severe combined immunodeficiency (SCID) (Macchi et al., 1995. Nature 377(6544):65-68). JAK3 knockout mice too exhibit SCID but do not display non-immune defects, suggesting that an inhibitor of JAK3 as an immunosuppressant would have restricted effects *in vivo* and therefore presents a promising drug for immunosuppression (Papageorgiou and Wikman 2004, Trends in Pharmacological Sciences 25(11):558-62).

20 Activating mutations for JAK3 have been observed in acute megakaryoblastic leukemia (AMKL) patients (Walters et al., 2006. Cancer Cell 10(1):65-75). These mutated forms of JAK3 can transform Ba/F3 cells to factor-independent growth and induce features of megakaryoblastic leukemia in a mouse model.

25 Diseases and disorders associated with JAK3 are further described, for example in WO 01/42246 and WO 2008/060301.

Several JAK3 inhibitors have been reported in the literature which may be useful in the medical field (O'Shea et al., 2004. Nat. Rev. Drug Discov. 3(7):555-64). A potent JAK3
30 inhibitor (CP-690,550) was reported to show efficacy in an animal model of organ transplantation (Changelian et al., 2003, Science 302(5646):875-888) and clinical trials (reviewed in: Pesu et al., 2008. Immunol. Rev. 223, 132-142). The CP-690,550 inhibitor is not selective for the JAK3 kinase and inhibits JAK2 kinase with almost equipotency (Jiang et al., 2008, J. Med. Chem. 51(24):8012-8018). It is expected that a selective JAK3 inhibitor that
35 inhibits JAK3 with greater potency than JAK2 may have advantageous therapeutic properties, because inhibition of JAK2 can cause anemia (Ghoreschi et al., 2009. Nature Immunol. 4, 356-360).

Heterocyclylaminopyrimidines as kinase inhibitors are described in European patent application with application N° 09 163 098.8.

Pyrimidine derivatives exhibiting JAK3 and JAK2 kinase inhibiting activities are described in WO-A 2008/009458. Pyrimidine compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3 are described in WO-A 2008/118822 and WO-A 2008/118823.


Fluoro substituted pyrimidine compounds as JAK3 inhibitors are described in WO 2010/118986 A. Further JAK inhibitors are described in International patent application with application N° PCT/EP2010/065700 and WO 2011/029807 A.

WO-A 2008/094602 relates to pyrazolopyrimidine as modulator of mitotic kinases. WO-A 2006/074985 relates to 5-membered, annelated heterocyclic pyrimidines as kinase inhibitors. US-A 2009/0203688 relates to pyrolopyrimidine compounds useful in one or more Protein tyrosine kinase mediated diseases.

Even though JAK inhibitors are known in the art there is a need for providing additional JAK inhibitors having at least partially more effective pharmaceutically relevant properties, like activity, selectivity especially over JAK2 kinase, and ADME properties.

Thus, an object of the present invention is to provide a new class of compounds as JAK inhibitors which preferably show selectivity over JAK2 and may be effective in the treatment or prophylaxis of disorders associated with JAK.

Accordingly, the present invention provides compounds of formula (I)



or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein

R^1 is H; $C(O)OR^3$; $C(O)R^3$; $C(O)N(R^3R^{3a})$; $S(O)_2N(R^3R^{3a})$; $S(O)N(R^3R^{3a})$; $S(O)_2R^3$; $S(O)R^3$; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; or C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more R^4 , which are the same or different;

R^{1a} , R^{1b} are independently selected from the group consisting of H; halogen, CN, OR^{1c} ; C_{1-6} alkyl; wherein C_{1-6} alkyl; is optionally substituted with one or more halogen, which are the same or different;

5

R^{1c} is H or C_{1-6} alkyl; wherein C_{1-6} alkyl; is optionally substituted with one or more halogen, which are the same or different;

R^3 , R^{3a} are independently selected from the group consisting of H; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more R^4 , which are the same or different;

10

R^4 is halogen; CN; $C(O)OR^5$; OR^5 ; $C(O)R^5$; $C(O)N(R^5R^{5a})$; $S(O)_2N(R^5R^{5a})$; $S(O)N(R^5R^{5a})$; $S(O)_2R^5$; $S(O)R^5$; $N(R^5)S(O)_2N(R^{5a}R^{5b})$; $N(R^5)S(O)N(R^{5a}R^{5b})$; SR^5 ; $N(R^5R^{5a})$; NO_2 ; $OC(O)R^5$; $N(R^5)C(O)R^{5a}$; $N(R^5)S(O)_2R^{5a}$; $N(R^5)S(O)R^{5a}$; $N(R^5)C(O)N(R^{5a}R^{5b})$; $N(R^5)C(O)OR^{5a}$; $OC(O)N(R^5R^{5a})$; or T^1 ;

15

R^5 , R^{5a} , R^{5b} are independently selected from the group consisting of H; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more halogen, which are the same or different;

20

R^2 is T^2 ; or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more R^6 , which are the same or different;

R^6 is T^2 ; halogen; CN; $C(O)OR^7$; OR^7 ; $C(O)R^7$; $C(O)N(R^7R^{7a})$; $S(O)_2N(R^7R^{7a})$; $S(O)N(R^7R^{7a})$; $S(O)_2R^7$; $S(O)R^7$; $N(R^7)S(O)_2N(R^{7a}R^{7b})$; $N(R^7)S(O)N(R^{7a}R^{7b})$; SR^7 ; $N(R^7R^{7a})$; NO_2 ; $OC(O)R^7$; $N(R^7)C(O)R^{7a}$; $N(R^7)S(O)_2R^{7a}$; $N(R^7)S(O)R^{7a}$; $N(R^7)C(O)N(R^{7a}R^{7b})$; $N(R^7)C(O)OR^{7a}$; or $OC(O)N(R^7R^{7a})$;

25

R^7 , R^{7a} , R^{7b} are independently selected from the group consisting of H; T^2 ; or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^8 , which are the same or different;

30

T^1 is C_{3-7} cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T^1 is optionally substituted with one or more R^{8a} , which are the same or different;

R^{8a} is C_{1-6} alkyl or halogen;

5

T^2 is C_{3-7} cycloalkyl; 4 to 7 membered saturated heterocyclyl; 1,2,3,4-tetrahydroquinoline 1,2,3,4-tetrahydroisoquinoline or indoline, wherein T^2 is optionally substituted with one or more R^9 , which are the same or different;

10 R^9 is halogen; CN; $C(O)OR^{10}$; OR^{10} ; oxo ($=O$); $C(O)R^{10}$; $C(O)N(R^{10}R^{10a})$; $S(O)_2N(R^{10}R^{10a})$; $S(O)N(R^{10}R^{10a})$; $S(O)_2R^{10}$; $S(O)R^{10}$; $N(R^{10})S(O)_2N(R^{10a}R^{10b})$; $N(R^{10})S(O)N(R^{10a}R^{10b})$; SR^{10} ; $N(R^{10}R^{10a})$; NO_2 ; $OC(O)R^{10}$; $N(R^{10})C(O)R^{10a}$; $N(R^{10})S(O)_2R^{10a}$; $N(R^{10})S(O)R^{10a}$; $N(R^{10})C(O)N(R^{10a}R^{10b})$; $N(R^{10})C(O)OR^{10a}$; $OC(O)N(R^{10}R^{10a})$; T^3 ; C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^{11} , which are the same or different;

15

R^{10} , R^{10a} , R^{10b} are independently selected from the group consisting of H; C_{1-4} alkyl; or T^3 wherein C_{1-4} alkyl is optionally substituted with one or more R^{12} , which are the same or different;

20 R^8 , R^{11} ; R^{12} are independently selected from the group consisting of halogen; CN; $C(O)OR^{13}$; OR^{13} ; $C(O)R^{13}$; $C(O)N(R^{13}R^{13a})$; $S(O)_2N(R^{13}R^{13a})$; $S(O)N(R^{13}R^{13a})$; $S(O)_2R^{13}$; $S(O)R^{13}$; $N(R^{13})S(O)_2N(R^{13a}R^{13b})$; $N(R^{13})S(O)N(R^{13a}R^{13b})$; SR^{13} ; $N(R^{13}R^{13a})$; NO_2 ; $OC(O)R^{13}$; $N(R^{13})C(O)R^{13a}$; $N(R^{13})S(O)_2R^{13a}$; $N(R^{13})S(O)R^{13a}$; $N(R^{13})C(O)N(R^{13a}R^{13b})$; $N(R^{13})C(O)OR^{13a}$; $OC(O)N(R^{13}R^{13a})$ and T^3 ;

25

T^3 is C_{3-7} cycloalkyl; phenyl; or 4 to 7 membered heterocyclyl, wherein T^3 is optionally substituted with one or more R^{14} , which are the same or different;

R^{13} , R^{13a} , R^{13b} are independently selected from the group consisting of H; and C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more halogen, which are the same or different;

30

R^{14} is halogen, CN, OR^{15} ; or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different;

R¹⁵ is H; or C₁₋₄ alkyl, wherein C₁₋₄ alkyl is optionally substituted with one or more halogen, which are the same or different.

- 5 In case a variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.

Within the meaning of the present invention the terms are used as follows:

10

“Alkyl” means a straight-chain or branched hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified.

15

“Alkenyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon may be replaced by a substituent as further specified.

20

“Alkynyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon may be replaced by a substituent as further specified.

25

“C₁₋₄ alkyl” means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. -CH₂-, -CH₂-CH₂-, -CH(CH₃)-, -CH₂-CH₂-CH₂-, -CH(C₂H₅)-, -C(CH₃)₂-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C₁₋₄ alkyl carbon may be replaced by a substituent as further specified.

30

“C₁₋₆ alkyl” means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: C₁₋₄ alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl; tert-butyl, n-pentyl, n-hexyl, or e.g. -CH₂-, -CH₂-CH₂-, -CH(CH₃)-, -CH₂-CH₂-CH₂-, -CH(C₂H₅)-, -C(CH₃)₂-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C₁₋₆ alkyl carbon may be replaced by a substituent as further specified.

35

“C₂₋₆ alkenyl” means an alkenyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: -CH=CH₂, -CH=CH-CH₃, -CH₂-CH=CH₂, -CH=CH-CH₂-CH₃, -CH=CH-

CH=CH₂, or e.g. -CH=CH-, when two moieties of a molecule are linked by the alkenyl group. Each hydrogen of a C₂₋₆ alkenyl carbon may be replaced by a substituent as further specified.

5 “C₂₋₆ alkynyl” means an alkynyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: -C≡CH, -CH₂-C≡CH, CH₂-CH₂-C≡CH, CH₂-C≡C-CH₃, or e.g. -C≡C- when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C₂₋₆ alkynyl carbon may be replaced by a substituent as further specified.

10 “C₃₋₇ cycloalkyl” or “C₃₋₇ cycloalkyl ring” means a cyclic alkyl chain having 3 - 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Preferably, cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified. The term “C₃₋₅ cycloalkyl” or “C₃₋₅ cycloalkyl ring” is defined accordingly.

15 “Halogen” means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.

20 “4 to 7 membered heterocyclyl” or “4 to 7 membered heterocycle” means a ring with 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)₂-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, 25 imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, 30 tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. The term “5 to 6 membered heterocyclyl” or “5 to 6 membered heterocycle” is defined accordingly.

“4 to 7 membered saturated heterocyclyl” or “4 to 7 membered saturated heterocycle” means a saturated 4 to 7 membered heterocyclyl or heterocycle. Examples are azetidine, oxetane,

thietane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, tetrahydropyran, imidazolidine, pyrimidine, piperazine, piperidine, morpholine, triazolidine, tetrazolidine or homopiperazine.

5

Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention. With respect to all preferred compounds of the formula (I) the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts.

10

In preferred embodiments of the present invention, the substituents mentioned below independently have the following meaning. Hence, one or more of these substituents can have the preferred or more preferred meanings given below.

15

Preferably, R^1 is C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen or OH, which are the same or different. More preferably, R^1 is C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different. More preferably, R^1 is CH_3 ; CH_2F ; CHF_2 ; CF_3 ; CH_2CH_3 ; CH_2CH_2F ; CH_2CHF_2 ; CH_2CF_3 ; $CH(F)CH_2F$; $CH(F)CHF_2$; $CH(F)CF_3$; $C(F_2)CH_2F$; $C(F_2)CHF_2$; or $C(F_2)CF_3$. Even more preferably, R^1 is CH_3 . Preferably, R^1 is CH_2CH_2OH .

20

Preferably, R^{1a} , R^{1b} are H.

25

Preferably, R^2 is T^2 ; or C_{1-6} alkyl substituted with at least 1 R^6 .

30

Preferably, R^2 is T^2 ; CH_2-T^2 ; $CH(CH_3)-T^2$; $CH(CH_2CH_3)-T^2$; $C(CH_3)_2-T^2$; or $CH(CH_2CH(CH_3)_2)-T^2$. Preferably, R^2 is $CH_2CH_2T^2$. More preferably, R^2 is T^2 . More preferably, R^2 is CH_2T^2 .

Preferably, R^2 is C_{1-6} alkyl substituted with at least 1 R^6 , provided that R^6 is other than T^2 .

Preferably, T^2 is piperidine; tetrahydropyran; cycloheptyl; cyclohexyl; or cyclopentyl, wherein T^2 is unsubstituted or substituted with one or more (preferably one) R^9 , which are the same or different. Preferably, T^2 is azetidine; or pyrrolidine, wherein T^2 is unsubstituted or substituted with one or more R^9 , which are the same or different.

5

Preferably, R^9 is $N(R^{10})S(O)_2R^{10a}$; $C(O)R^{10}$; $S(O)_2R^{10}$; or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^{11} , which are the same or different. Preferably, R^9 is $N(R^{10})C(O)R^{10a}$; $C(O)OR^{10}$; or $C(O)N(R^{10})R^{10a}$. More preferably, R^9 is CH_3 ; $S(O)_2CH_3$; $C(O)CH_2OCH_3$. Also more preferably, R^9 is CH_2CH_3 ; CH_2CHF_2 ; $CH_2C(O)NHCH_3$; $CH_2C(O)NHCH(CH_3)_2$; CH_2CH_2OH ; $CH_2CH_2OCH_3$; $CH_2CH_2SCH_3$; CH_2CH_2CN ; CH_2CN ; $CH_2CH_2S(O)_2CH_3$; $(CH_2)_3OCH_3$; $(CH_2)_3S(O)_2CH_3$; $C(O)CF_3$; $C(O)CH_2N(CH_3)_2$; $NHC(O)CH_3$; $C(O)CH_2CH_2OCH_3$; $C(O)CH_2CH_2SCH_3$; $C(O)CH_2CH_2S(O)_2CH_3$; $C(O)CH_2CN$; $C(O)T^3$; $S(O)_2CH_2CH_3$; $S(O)_2CH(CH_3)_2$; $S(O)_2T^3$; $C(O)OCH_3$; $C(O)OCH_2CH_3$; $C(O)OCH_2CH_2F$; $C(O)OCH_2CH_2OCH_3$; $C(O)N(CH_3)_2$; $C(O)NHCH_2CH_3$; $C(O)NHT^3$.

15

Preferably, T^3 is tetrahydropyran; or cyclopropane.

Preferably, R^6 is $N(R^{10})S(O)_2R^{10a}$; $C(O)R^{10}$; or $S(O)_2R^{10}$.

20

Compounds of formula (I) in which some or all of the above-mentioned groups have the preferred meanings are also an object of the present invention.

Further preferred compounds of the present invention are selected from the group consisting of

25

N-(1-Methyl-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

N-(3-(6-(1-methyl-1H-pyrazol-4-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)methanesulfonamide;

30

N-(1-methyl-1H-pyrazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

- N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-((1-methylpiperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 5 Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-cyclohexyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 10 N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- Rac-cis-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 15 amine;
- N-(1-Methyl-1H-pyrazol-4-yl)-1-(2-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-Methyl-1H-pyrazol-4-yl)-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 20 1-(Cyclohexylmethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-(1-Cyclohexylethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-(1-Cyclohexylpropyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 25 d]pyrimidin-6-amine;
- 1-Cycloheptyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 2-methoxy-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- N-(4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)acetamide;
- 30 1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one;
- 3-(4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile;

- 3-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile;
- 3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-oxopropanenitrile;
- 5 3-methoxy-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propan-1-one;
- (3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone;
- 2-(dimethylamino)-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-
- 10 d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(ethylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 15 1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(cyclopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(1-(methylsulfonyl)piperidin-3-yl)ethyl)-1H-
- 20 pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(2-methoxyethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- ethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 25 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylthio)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- methyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 2-(4-((1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-
- 30 yl)amino)-1H-pyrazol-1-yl)ethanol;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile;

- 1-((1-(ethylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(cyclopropylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 5 2-fluoroethyl 3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 2-methoxyethyl 3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 10 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 2,2,2-trifluoro-1-(3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 15 3-(3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidin-1-yl)propanenitrile;
- Rac-trans-2-(4-((1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-1H-pyrazol-1-yl)ethanol;
- N-ethyl-3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;
- 20 N-cyclopropyl-3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;
- 3-(3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)propanenitrile;
- 25 2-(3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile;
- 1-((1-ethylpiperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-(3-(((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylthio)propan-1-one;
- 30 3-(3-(((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile;
- 1-((1-(3-methoxypropyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

- 1-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one;
 2-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile;
- 5 N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(3-(methylsulfonyl)propyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide;
- 10 N-methyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide;
 N,N-dimethyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;
- 15 2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanol;
 1-((1-(2,2-difluoroethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; and
 N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)acetamide.
- 20

A first preferred group of compounds are compounds as shown in examples 1 to 21 and a second group as shown in examples 22 to 68.

- 25 Prodrugs of the compounds of the present invention are also within the scope of the present invention.

"Prodrug" means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically. Examples of a prodrug are compounds, wherein the amino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g. acetyloxy, palmitoyloxy,

30

pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy or wherein the carboxyl group is esterified or amidated. These compounds can be produced from compounds of the present invention according to well-known methods.

- 5 Metabolites of compounds of formula (I) are also within the scope of the present invention.

The term “metabolites” refers to all molecules derived from any of the compounds according to the present invention in a cell or organism, preferably mammal.

- 10 Preferably the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions.

The structure of the metabolites of the compounds according to the present invention will be obvious to any person skilled in the art, using the various appropriate methods.

15

Where tautomerism, e.g. keto-enol tautomerism, of compounds of general formula (I) may occur, the individual forms, e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio. The same applies for stereoisomers, e.g. enantiomers, cis/trans isomers, conformers and the like.

20

If desired, isomers can be separated by methods well known in the art, e.g. by liquid chromatography. The same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the
25 resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials.

30

The compounds of formula (I) may exist in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of formula (I) may exist as polymorphs, which are included within the scope of the present invention. Polymorphic forms of compounds of formula (I) may be characterized and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning calorimetry

(DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic resonance (ssNMR).

In case the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula (I) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

Throughout the invention, the term “pharmaceutically acceptable” means that the corresponding compound, carrier or molecule is suitable for administration to humans. Preferably, this term means approved by a regulatory agency such as the EMEA (Europe)

and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.

The present invention furthermore includes all solvates of the compounds according to the invention.

According to the present invention “JAK” comprises all members of the JAK family (e.g. JAK1, JAK2, JAK3, and TYK2).

According to the present invention, the expression “JAK1” or “JAK1 kinase” means “Janus kinase 1”. The human gene encoding JAK1 is located on chromosome 1p31.3.

According to the present invention, the expression “JAK2” or “JAK2 kinase” means “Janus kinase 2”. The human gene encoding JAK2 is located on chromosome 9p24.

According to the present invention, the expression “JAK3” or “JAK3 kinase” means “Janus kinase 3”. The gene encoding JAK3 is located on human chromosome 19p13.1 and it is predominantly in hematopoietic cells. JAK3 is a cytoplasmic protein tyrosine kinase that associates with the gamma-chain of the interleukin 2 (IL-2) receptor. This chain also serves as a component for the receptors of several lymphotropic cytokines, including interleukins IL-4, IL-7, IL-9, IL-15 and IL-21 (Schindler et al., 2007. J. Biol. Chem. 282(28):20059-63). JAK3 plays a key role in the response of immune cells to cytokines, especially in mast cells, lymphocytes and macrophages. Inhibition of JAK3 has shown beneficial effects in the prevention of transplant rejection (Changelian et al., 2003, Science 302(5646):875-888).

Moreover, according to the present invention, the expression “JAK3” or “JAK3 kinase” includes mutant forms of JAK3, preferably JAK3 mutants found in acute megakaryoblastic leukemia (AMKL) patients. More preferred, these mutants are single amino acid mutations. Activating JAK3 mutations were observed in acute megakaryoblastic leukemia (AMKL) patients (Walters et al., 2006. Cancer Cell 10(1):65-75). Therefore, in a preferred embodiment, the expression “JAK” also includes a JAK3 protein having a V722I or P132T mutation.

According to the present invention, the expression “TYK2” or “TYK2 kinase” means “Protein-Tyrosine kinase 2”. The JAK3 and TYK2 genes are clustered on chromosome 19p13.1 and 19p13.2, respectively.

As shown in the examples, compounds of the invention were tested for their selectivity for JAK3 over JAK2 kinases. As shown, all tested compounds bind JAK3 more selectively than, JAK2 (see table 5 below).

- 5 Consequently, the compounds of the present invention are considered to be useful for the prevention or treatment of diseases and disorders associated with JAK, for example immunological, inflammatory, autoimmune, or allergic disorders, transplant rejection, Graft-versus-Host-Disease or proliferative diseases such as cancer.
- 10 In a preferred embodiment, the compounds of the present invention are selective JAK3 inhibitors.

Equally preferred are dual JAK1/JAK3 inhibitors.

- 15 The compounds of the present invention may be further characterized by determining whether they have an effect on JAK3, for example on its kinase activity (Changelian et al., 2003, Science 302(5646):875-888 and online supplement; Yang et al., 2007. Bioorg. Med. Chem. Letters 17(2): 326-331).
- 20 Briefly, JAK3 kinase activity can be measured using a recombinant GST-JAK3 fusion protein comprising the catalytic domain (JH1 catalytic domain). JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1; 100 µg/ml) as a substrate. The plates are washed and recombinant JAK3 JH1:GST protein (100 ng/well) with or without inhibitors is incubated at room temperature
- 25 for 30 minutes. The a HPR-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine) (Changelian et al., 2003, Science 302(5646):875-888 and online supplement).

- 30 A cell-based assays (TF-1 cell proliferation) was described to assess the inhibitory activity of small molecule drugs toward JAK2 or JAK3-dependent signal transduction (Chen et al., 2006. Bioorg. Med. Chem. Letters 16(21): 5633-5638).

The present invention provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient together with a

pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.

5 “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a
10 compound of the present invention and a pharmaceutically acceptable carrier.

The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not
15 limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions. Suitable pharmaceutical excipients
20 include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-
25 release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such
30 compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

A pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or other JAK inhibitors. Further bioactive compounds may be steroids, leukotriene antagonists, cyclosporine or rapamycin.

5

The compounds of the present invention or pharmaceutically acceptable salt(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order. When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.

10

It is further included within the present invention that the compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) is administered in combination with another drug or pharmaceutically active agent and/or that the pharmaceutical composition of the invention further comprises such a drug or pharmaceutically active agent.

15

In this context, the term “drug or pharmaceutically active agent” includes a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.

20

“Combined” or “in combination” or “combination” should be understood as a functional coadministration, wherein some or all compounds may be administered separately, in different formulations, different modes of administration (for example subcutaneous, intravenous or oral) and different times of administration. The individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.

25

30

For example, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Suitable examples of pharmaceutically active agents which may be employed in combination with the compounds of the present invention and their salts for rheumatoid arthritis therapy include: immunosuppressants such as amtolmetin guacil,

mizoribine and rimexolone; anti-TNF α agents such as etanercept, infliximab, Adalimumab, Anakinra, Abatacept, Rituximab; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychloroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.

In particular, the treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy. Accordingly, the compounds of the invention can also be used in combination with existing therapeutic agents for the treatment proliferative diseases such as cancer.

Suitable agents to be used in combination include:

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like paclitaxel and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

(iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro- 2,3 -methylenedioxyanilino)-7- [2-(4-methylpiperazin- 1 -yl)ethoxy] -5 -tetrahydropyran- 4-yloxy-quinazoline (AZD0530) and N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);

(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™] and the anti-erbB1 antibody cetuximab [C225]); such inhibitors also include, for example, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), Λ /(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido- Λ /(3-chloro-4-fluorophenyl)-7-(3- morpholinopropoxy)-quinazolin-4-amine (CI 1033) and erbB2 tyrosine kinase inhibitors such as lapatinib), inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006)) and inhibitors of cell signalling through MEK and/or Akt kinases;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1 -methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SU1 1248 (sunitinib; WO 01/60814), and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);

(vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Application WO 99/02166;

(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense agent;

- 5 (viii) gene therapy approaches, including approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and (ix) immunotherapeutic
10 approaches, including ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic
15 antibodies.

Further combination treatments are described in WO-A 2009/008992 and WO-A 2007/107318, incorporated herein by reference.

- 20 Accordingly, the individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.

The pharmaceutical compositions of the present invention include compositions suitable for
25 oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of
30 pharmacy.

In practical use, the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form

of preparation desired for administration, *e.g.*, oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.

Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally, for example, as liquid drops or spray.

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene

glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

5 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example,
10 water, ethanol, polyol (*e.g.*, glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral,
15 rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of formula (I) are administered orally.

20 The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.

25 A therapeutically effective amount of a compound of the present invention will normally depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration. However, an effective amount of a compound of formula (I) for the treatment of an inflammatory disease, for example rheumatoid arthritis (RA), will
30 generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70 kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a

pharmaceutically acceptable salt, prodrug or metabolite thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.

- 5 As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.

- 10 Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

- 15 Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt thereof for use as a medicament.

- 20 Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing a disease or disorder associated with JAK.

In the context of the present invention, a disease or disorder associated with JAK is defined as a disease or disorder where JAK is involved.

- 25 In a preferred embodiment, wherein the diseases or disorder is associated with JAK is an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.

- 30 Consequently, another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.

Inflammation of tissues and organs occurs in a wide range of disorders and diseases and in certain variations, results from activation of the cytokine family of receptors. Exemplary inflammatory disorders associated with activation of JAK include, in a non-limiting manner, skin inflammation due radiation exposure, asthma, allergic inflammation and chronic inflammation.

According to the present invention, an autoimmune disease is a disease which is at least partially provoked by an immune reaction of the body against own components, for example proteins, lipids or DNA. Examples of organ-specific autoimmune disorders are insulin-dependent diabetes (Type I) which affects the pancreas, Hashimoto's thyroiditis and Graves' disease which affect the thyroid gland, pernicious anemia which affects the stomach, Cushing's disease and Addison's disease which affect the adrenal glands, chronic active hepatitis which affects the liver; polycystic ovary syndrome (PCOS), celiac disease, psoriasis, inflammatory bowel disease (IBD) and ankylosing spondylitis. Examples of non-organ-specific autoimmune disorders are rheumatoid arthritis, multiple sclerosis, systemic lupus and myasthenia gravis.

Type I diabetes ensues from the selective aggression of autoreactive T-cells against insulin secreting beta-cells of the islets of Langerhans. Targeting JAK3 in this disease is based on the observation that multiple cytokines that signal through the JAK pathway are known to participate in the T-cell mediated autoimmune destruction of beta-cells. Indeed, a JAK3 inhibitor, JANEX-1 was shown to prevent spontaneous autoimmune diabetes development in the NOD mouse model of type I diabetes.

In a preferred embodiment, the autoimmune disease is selected from the group consisting of rheumatoid arthritis (RA), inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis), psoriasis, systemic lupus erythematosus (SLE), and multiple sclerosis (MS).

Rheumatoid arthritis (RA) is a chronic progressive, debilitating inflammatory disease that affects approximately 1% of the world's population. RA is a symmetric polyarticular arthritis that primarily affects the small joints of the hands and feet. In addition to inflammation in the synovium, the joint lining, the aggressive front of tissue called pannus invades and destroys local articular structures (Firestein 2003, Nature 423:356-361).

Inflammatory bowel disease (IBD) is characterized by a chronic relapsing intestinal inflammation. IBD is subdivided into Crohn's disease and ulcerative colitis phenotypes. Crohn disease involves most frequently the terminal ileum and colon, is transmural and discontinuous. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers. In approximately 10% of cases confined to the rectum and colon, definitive classification of Crohn's disease or ulcerative colitis cannot be made and are designated 'indeterminate colitis.' Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Neutrophil-induced injuries may be prevented by the use of neutrophils migration inhibitors (Asakura et al., 2007, World J Gastroenterol. 13(15):2145-9).

Psoriasis is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis (Schön et al., 2005, New Engl. J. Med. 352:1899-1912).

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Human SLE is characterized at early stages by the expansion of long-lasting autoreactive CD4⁺ memory cells (D'Cruz et al., 2007, Lancet 369(9561):587-596).

Multiple sclerosis (MS) is an inflammatory and demyelating neurological disease. It has been considered as an autoimmune disorder mediated by CD4⁺ type 1 T helper cells, but recent studies indicated a role of other immune cells (Hemmer et al., 2002, Nat. Rev. Neuroscience 3, 291-301).

Mast cells express JAK3 and JAK3 is a key regulator of the IgE mediated mast cell responses including the release of inflammatory mediators. JAK3 was shown to be a valid target in the treatment of mast cell mediated allergic reaction. Allergic disorders associated with mast cell activation include Type I immediate hypersensitivity reactions such as allergic rhinitis (hay fever), allergic urticaria (hives), angioedema, allergic asthma and anaphylaxis, for example anaphylactic shock. These disorders may be treated or prevented by inhibition of JAK3 activity, for example, by administration of a JAK3 inhibitor according to the present invention.

Transplant rejection (allograft transplant rejection) includes, without limitation, acute and chronic allograft rejection following for example transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea. It is known that T cells play a central role in the specific immune response of allograft rejection. Hyperacute, acute and chronic organ transplant rejection may be treated. Hyperacute rejection occurs within minutes of transplantation. Acute rejection generally occurs within six to twelve months of the transplant. Hyperacute and acute rejections are typically reversible where treated with immunosuppressant agents. Chronic rejection, characterized by gradual loss of organ function, is an ongoing concern for transplant recipients because it can occur anytime after transplantation.

Graft-versus-host disease (GVHD) is a major complication in allogeneic bone marrow transplantation (BMT). GVHD is caused by donor T cells that recognize and react to recipient differences in the histocompatibility complex system, resulting in significant morbidity and mortality. JAK3 plays a key role in the induction of GVHD and treatment with a JAK3 inhibitor, JANEX-1, was shown to attenuate the severity of GVHD (reviewed in Cetkovic-Cvrlje and Ucken, 2004).

In a preferred embodiment, the inflammatory disease is an eye disease.

Dry eye syndrome (DES, also known as keratoconjunctivitis sicca) is one of the most common problems treated by eye physicians. Sometimes DES is referred to as dysfunctional tear syndrome (Jackson, 2009. Canadian Journal Ophthalmology 44(4), 385-394). DES affects up to 10% of the population between the ages of 20 to 45 years, with this percentage increasing with age. Although a wide variety of artificial tear products are available, these products provide only transitory relief of symptoms. As such, there is a need for agents, compositions and therapeutic methods to treat dry eye.

As used herein, "dry eye disorder" is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface." (Lemp, 2007. "The Definition and Classification of Dry Eye Disease: Report of the Definition

and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92). Dry eye is also sometimes referred to as keratoconjunctivitis sicca. In some embodiments, the treatment of the dry eye disorder involves ameliorating a particular symptom of dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.

Uveitis is the most common form of intraocular inflammation and remains a significant cause of visual loss. Current treatments for uveitis employs systemic medications that have severe side effects and are globally immunosuppressive. Clinically, chronic progressive or relapsing forms of non-infectious uveitis are treated with topical and/or systemic corticosteroids. In addition, macrolides such as cyclosporine and rapamycin are used, and in some cases cytotoxic agents such as cyclophosphamide and chlorambucil, and antimetabolites such as azathioprine, methotrexate, and leflunomide (Srivastava et al., 2010. Uveitis: Mechanisms and recent advances in therapy. Clinica Chimica Acta, doi:10.1016/j.cca.2010.04.017).

Further eye diseases, combination treatments and route of administration are described for example in WO-A 2010/039939, which is hereby incorporated herein by reference.

In a further preferred embodiment, the disease or disorder associated with JAK is a proliferative disease, especially cancer.

Diseases and disorders associated especially with JAK are proliferative disorders or diseases, especially cancer.

Therefore, another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing a proliferative disease, especially cancer.

Cancer comprises a group of diseases characterized by uncontrolled growth and spread of abnormal cells. All types of cancers generally involve some abnormality in the control of cell growth, division and survival, resulting in the malignant growth of cells. Key factors contributing to said malignant growth of cells are independence from growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential,

sustained angiogenesis, tissue invasion and metastasis, and genome instability (Hanahan and Weinberg, 2000. The Hallmarks of Cancer. Cell 100, 57-70).

Typically, cancers are classified as hematological cancers (for example leukemias and lymphomas) and solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).

The JAK inhibitors of the present invention may also be useful in treating certain malignancies, including skin cancer and hematological malignancy such as lymphomas and leukemias.

10

Especially cancers in which the JAK-STAT signal transduction pathway is activated, for example due to activation of JAK3 are expected to respond to treatment with JAK3 inhibitors. Examples of cancers harboring JAK3 mutations are acute megakaryoblastic leukemia (AMKL) (Walters et al., 2006. Cancer Cell 10(1):65-75) and breast cancer (Jeong et al., 2008. Clin. Cancer Res. 14, 3716-3721).

15

Proliferative diseases or disorders comprise a group of diseases characterized by increased cell multiplication as observed in myeloproliferative disorders (MPD) such as polycythemia vera (PV).

20

Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with JAK.

25

Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease.

30

Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease, especially cancer.

In the context of these uses of the invention, diseases and disorders associated with JAK are as defined above.

- 5 Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of diseases and disorders associated with JAK, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.
- 10 Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according
- 15 to present invention or a pharmaceutically acceptable salt thereof.

- Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof a proliferative disease, especially cancer, wherein the method comprises the administration to said patient a therapeutically effective
- 20 amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.


- In the context of these methods of the invention, diseases and disorders associated with JAK are as defined above.

- 25 As used herein, the term "treating" or "treatment" is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.

- 30 All embodiments discussed above with respect to the pharmaceutical composition of the invention also apply to the above mentioned first or second medical uses or methods of the invention.

In general, compounds of the present invention may be prepared according to a method comprising the step of


reacting a compound of formula (II)




wherein R^1 , R^{1a} , R^{1b} have the meaning as indicated above, with a compound of formula R^2 -X, wherein R^2 has the meaning as indicated above and X is a suitable leaving group to yield a compound of formula (I).

In a further embodiment compounds of the present invention are prepared according to a method for the preparation comprising the step of

reacting a compound of formula (III)



wherein R^2 has the meaning as indicated above, with a compound of formula (IV)




wherein R^1 , R^{1a} , R^{1b} have the meaning as indicated above to yield a compound of formula (I).

Exemplary routes for the preparation of compounds of the present invention are described below. It is clear to a practitioner in the art to combine or adjust such routes especially in combination with the introduction of activating or protective chemical groups.


25

A general route for the preparation of compounds according to present invention is outlined in Scheme 1.



Scheme 1

Compounds of the present invention can also be prepared according to a general route outlined in Scheme 2



Scheme 2

It will be appreciated that novel intermediates described herein form another embodiment of the present invention.

Examples

Analytical Methods

NMR spectra were obtained on a Bruker dpx400. LC-MS was carried out on an Agilent 1100 using a ZORBAX[®] SB-C18, 4.6 x 150 mm, 5 micron column or a ZORBAX[®] SB-C18, 4.6 x 75 mm, 3.5 micron column or a Phenomenex Gemini-NX C18, 4.6 x 150 mm, 5 micron column. Column flow was 1mL/min and solvents used were water and acetonitrile (0.1% formic acid) with an injection volume of 10uL. Wavelengths were 254 and 210 nm. Methods are described below.

Method A

- 10 Column: Gemini C18, 3 x 30 mm, 3 microns Flow: 1.2 mL/min. Gradient: Table 1

Table 1

Time (min)	Water	Acetonitrile
0	95	5
3	5	95
4.5	5	95
4.6	95	5
5.00	STOP	

Method B

- 15 Column: ZORBAX[®] SB-C18, 4.6 x 150 mm, 5 microns. Flow: 1 mL/min. Gradient: Table 2

Table 2

Time (min)	Water	Acetonitrile
0	95	5
11	5	95
13	5	95
13.01	95	5
14.00	STOP	

Method C

- 20 Column: Phenomenex Gemini-NX C18, 4.6 x 150 mm, 5 microns. Flow: 1 mL/min. Gradient: Table 3

Table 3

Time (min)	Water	Acetonitrile
0	95	5
11	5	95
13	5	95
13.01	95	5
16.00	95	5
16.01	STOP	

Abbreviations

5


Table 4

Boc	Tert-Butoxycarbonyl
d	Doublet
dd	Doubledoublet
DMF	N,N'-Dimethylformamide
DMSO	N,N'-dimethylsulfoxide
DP	Drug pulldown
DTT	Dithiothreitol
EDTA	Ethylenediaminetetraacetic acid
EtOAc	Ethyl acetate
eq	Equivalents
g	Grams
h	Hours
HCl	Hydrochloric acid
H ₂ O	Water
HPLC	High performance liquid chromatography
IC ₅₀	50% Maximum inhibition concentration
L	Litres
LC-MS	Liquid chromatography mass spectroscopy
m	Multiplet
M	Molar
mg	Milligrams

MgSO ₄	Magnesium Sulphate
min	Minutes
mL	Millilitres
mm	Millimetres
mmol	Millimoles
μL	Microlitres
nm	Nanometres
NMR	Nuclear magnetic resonance
PBS	Phosphate buffered saline
rpm	Revolutions per minute
rt	Room temperature
RT	Retention time
s	Singlet
t	Triplet
td	Triplet of doublets
tert	Tertiary
wt	Weight

Intermediates

Intermediate A: *N*-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine




- 5 A solution of 4-nitropyrazole (300mg, 2.65mmol), potassium carbonate (2eq) and methyl iodide (1.1eq) in acetonitrile (10mL) was heated at 60°C for 18h. After cooling to rt the mixture was diluted with EtOAc and washed with H₂O. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The crude residue was dissolved in methanol (10mL), palladium on carbon (50mg, 10%wt) was added and the reaction was stirred under a
- 10 balloon of hydrogen for 18h. The resulting mixture was filtered through Celite and the filtrate concentrated *in vacuo* to give 1-methyl-1H-pyrazol-4-amine.

A suspension of 1-methyl-1H-pyrazol-4-amine (320mg, 3.2mmol), 6-chloro-1H-pyrazolo[3,4-*d*]pyrimidine (500mg, 3.2mmol) and HCl (25μL, 4M solution in dioxane) in isopropanol

(2mL) was heated in the microwave at 140°C for 1h. After cooling to rt, the mixture was filtered and the resulting solid washed with cold isopropanol and diethyl ether to give the title product. ¹H NMR (d₆-DMSO) δ 9.72 (s, 1H), 8.95 (s, 1H), 8.05 (s, 1H), 7.96 (s, 1H), 7.58 (s, 1H), 3.83 (s, 3H); LC-MS method B, (ES+) 216.1, RT = 4.85 min.

5

Example 1: *N*-(1-Methyl-1H-pyrazol-4-yl)-1-((1-(methanesulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine




10 A solution of 3-piperidinemethanol (500mg, 4.35mmol) and methanesulfonyl chloride (3eq) in dichloromethane (10mL) and pyridine (5mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give (1-(methanesulfonyl)piperidin-3-yl)methyl methanesulfonate.

15

A suspension of intermediate A (80mg, 0.37mmol) and sodium hydride (1.1eq) in DMF (3mL) was stirred at rt for 30min. Then, (1-(methanesulfonyl)piperidin-3-yl)methyl methanesulfonate (1.1eq) was added and the reaction stirred at rt for 18h. The mixture was then diluted with EtOAc and washed with H₂O and then brine. The organic phase was
20 collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (d₆-DMSO) δ 9.87 (br s, 1H), 8.91 (br s, 1H), 8.05 (s, 1H), 8.03 (s, 1H), 7.58 (s, 1H), 4.29 (s, 2H), 3.84 (s, 3H), 3.34-3.46 (m, 2H), 2.79 (s, 3H), 2.66-2.75 (m, 2H), 2.23-2.28 (m, 1H), 1.74-1.80 (m, 1H), 1.63-1.67 (m, 1H), 1.39-1.50 (m, 1H), 1.07-1.13 (m, 1H); LC-MS method B, (ES+)
25 391.0, RT = 6.76 min.

Example 2: *N*-(3-(6-(1-methyl-1H-pyrazol-4-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)methanesulfonamide




5 A solution of 3-chloropropylamine hydrochloride (500mg, 4.31mmol) and methanesulfonyl chloride (1.5eq) in pyridine (5mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O, then aqueous 1M HCl solution and then saturated aqueous sodium hydrogen carbonate solution. The organic phase was collected, dried and concentrated *in vacuo* to give N-(3-chloropropyl)methanesulfonamide.

10

A suspension of intermediate A (80mg, 0.37mmol) and sodium hydride (1.1eq) in DMF (3mL) was stirred at rt for 30min. Then, N-(3-chloropropyl)methanesulfonamide (1.1eq) was added and the reaction stirred at rt for 18h. The resultant mixture was then diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (d₆-DMSO) δ 9.84 (br s, 1H), 8.90 (s, 1H), 8.09 (br s, 1H), 8.04 (s, 1H), 7.56 (s, 1H), 7.10-7.14 (m, 1H), 4.36-4.40 (m, 2H), 3.85 (s, 3H), 2.99-3.04 (m, 2H), 2.86 (s, 3H), 2.03-2.07 (m, 2H); LC-MS method B, (ES⁺) 351.0, RT = 5.67 min.

20

Example 3: *N*-(1-methyl-1H-pyrazol-4-yl)-1-(1-(methanesulfonyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine




25

A solution of 4-hydroxypiperidine (400mg, 4.0mmol), triethylamine (3eq) and methanesulfonyl chloride (3eq) in dichloromethane (10 mL) was stirred at rt for 4h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then
5 brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 1-(methylsulfonyl)piperidin-4-yl methanesulfonate.

A suspension of intermediate A (80mg, 0.37mmol), potassium carbonate (2eq) and 1-(methylsulfonyl)piperidin-4-yl methanesulfonate (1eq) in DMF (3mL) was stirred at 80°C for
10 18h. The resultant mixture was then cooled to rt, diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (d₆-DMSO) δ 9.83 (s, 1H), 8.91 (s, 1H), 8.04 (s, 1H), 7.97 (s, 1H), 7.62 (s, 1H), 4.76 (br s, 1H), 3.85 (s, 3H), 3.73-3.76 (m, 2H), 2.97-3.06 (m, 2H), 2.97 (s, 3H), 2.22-2.28 (m, 2H), 2.06-2.09 (m, 2H); LC-MS method B, (ES⁺) 377.0, RT = 6.57 min.
15

Example 4: *N*-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine
20




A solution of 2,2-difluoroethanol (0.38mL, 6.1mmol), methanesulfonyl chloride (2eq) and pyridine (5mL) in dichloromethane (10mL) was stirred at rt for 16h. The mixture was then
25 diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 2,2-difluoromethane sulfonate.

A solution of 4-nitropyrazole (300mg, 2.65mmol), potassium carbonate (2eq) and 2,2-difluoromethane sulfonate (1.1eq) in acetonitrile (10mL) was heated at 60°C for 18h. After cooling to rt the mixture was diluted with EtOAc and washed with H₂O. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The crude residue was dissolved in methanol (10mL), palladium on carbon (50mg, 10%wt) was added and the reaction was stirred under a balloon of hydrogen for 18h. The resulting mixture was filtered through Celite and the filtrate concentrated *in vacuo* to give 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine.

A suspension of 6-chloro-1H-pyrazolo[3,4-d]pyrimidine (0.10g, 0.70mmol), 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine (1eq) and HCl (25μL of a 4M solution in dioxane) in isopropanol (2mL) was heated in the microwave at 140°C for 1h. After cooling to rt, the mixture was filtered and the resulting solid washed with cold isopropanol and diethyl ether to yield N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine.

A suspension of N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (60mg, 0.23mmol), potassium carbonate (2eq) and (1-(methylsulfonyl)piperidin-3-yl)methyl methanesulfonate (1eq) in DMF (3mL) was stirred at 80°C for 18h. LC-MS indicated reaction that the reaction was not complete so further (1-(methylsulfonyl)piperidin-3-yl)methyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 18h. The resultant mixture was then cooled to rt, diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (d₆-DMSO) δ 9.91 (s, 1H), 8.93 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.70 (s, 1H), 6.20-6.50 (m, 1H), 4.62 (td, 2H), 4.28-4.32 (m, 2H), 3.37-3.45 (m, 2H), 2.78 (s, 3H), 2.61-2.76 (m, 2H), 2.07-2.12 (m, 1H), 1.62-1.77 (m, 2H), 1.47-1.52 (m, 1H), 1.09-1.17 (m, 1H); LC-MS method B, (ES+) 441.0, RT = 7.49 min.

Example 5: N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine




A solution of N-Boc-piperidine-3-methanol (0.25g, 1.16mmol) and methanesulfonyl chloride (2eq) in pyridine (8mL) was stirred at rt for 48h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected, dried using a hydrophobic frit then concentrated *in vacuo* to give tert-butyl-3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate.

A suspension of 6-chloro-1H-pyrazol[3,4-d]pyrimidine (0.12g, 0.78mmol), tert-butyl-3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at rt for 16h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected, dried using a hydrophobic frit then concentrated *in vacuo* to give tert-butyl-3-((6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate.

To a solution of tert-butyl-3-((6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate in dichloromethane (5mL) was added an excess of trifluoroacetic acid. The mixture was stirred at rt for 2h. The mixture was diluted with dichloromethane then washed with saturated aqueous sodium bicarbonate. The organic phase was collected, dried using a hydrophobic frit then concentrated *in vacuo* to give 6-chloro-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine.


A suspension of 6-chloro-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine (0.13g, 0.51mmol), 1-methyl-1H-pyrazol-4-amine (1.5eq) and HCl (1.6eq of a 4M solution in dioxane) in isopropanol (2mL) was heated in the microwave at 140°C for 1h. The mixture was filtered and the filtrate concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title product. ¹H NMR (CD₃OD) δ 8.84 (s, 1H), 8.05 (s, 1H), 7.97 (s, 1H), 7.70 (s, 1H), 4.28 (d, 2H), 3.91 (s, 3H), 2.97-3.02 (m, 2H), 2.49-2.58 (m, 2H), 2.31-2.35 (m, 1H), 1.75-1.83 (m, 2H), 1.48-1.55 (m, 1H), 1.26-1.35 (m, 1H); LC-MS method B, (ES+) 313, RT = 4.13 min.

Example 6: *N-(1-methyl-1H-pyrazol-4-yl)-1-((1-methylpiperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*



A suspension of intermediate A (75mg, 0.35mmol), 3-(chloromethyl)-1-methylpiperidine hydrochloride (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 50°C for 18h then at 80°C for 6h. LC-MS indicated that the reaction was not complete so further 3-(chloromethyl)-1-methylpiperidine hydrochloride (1eq) was added and the mixture stirred at 80°C for 18h. After cooling to rt, the mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title compound. ¹H NMR (d₆-DMSO) δ 9.79 (s, 1H), 8.89 (s, 1H), 8.02 (s, 2H), 7.61 (s, 1H), 4.23 (d, 2H), 3.83 (s, 3H), 2.51-2.54 (m, 2H), 2.18-2.22 (m, 1H), 2.08 (s, 3H), 1.90-1.95 (m, 1H), 1.79-1.84 (m, 1H), 1.62-1.66 (m, 1H), 1.54-1.57 (m, 1H), 1.37-1.46 (m, 1H); LC-MS method B, (ES+) 327, RT = 4.09 min.

Example 7: *Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*




A solution of cis-2-methylcyclohexanol (0.25g, 2.19mmol) and methanesulfonyl chloride (2eq) in pyridine (8mL) was stirred at rt for 16h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo* to give cis-2-methylcyclohexyl methanesulfonate.

A suspension of intermediate A (0.1g, 0.47mmol), cis-2-methylcyclohexyl methanesulfonate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 50h. LC-MS indicated that the reaction was not complete so further cis-2-methylcyclohexyl

methanesulfonate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for 24h. Further *cis*-2-methylcyclohexyl methanesulfonate (1eq) and potassium carbonate (1eq) was then added and the mixture stirred at 80°C for a further 24h. After cooling to rt, the mixture was filtered and the solid washed with dichloromethane. The filtrate was washed with H₂O. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title product. ¹H NMR (d₆-DMSO) δ 9.83 (s, 1H), 8.92 (s, 1H), 8.06 (s, 1H), 7.94 (s, 1H), 7.64 (s, 1H), 4.17-4.22 (m, 1H), 3.84 (s, 3H), 2.13-2.15 (m, 1H), 2.00-2.02 (m, 1H), 1.85-1.88 (m, 3H), 1.74-1.78 (m, 1H), 1.46-1.49 (m, 1H), 1.35-1.41 (m, 1H), 1.18-1.24 (m, 1H), 0.57 (d, 3H); LC-MS method B, (ES⁺) 312, RT = 9.06 min.

Example 8: *1-cyclohexyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*




A solution of cyclohexanol (0.25g, 2.50mmol) and methanesulfonyl chloride (2eq) in pyridine (8ml) was stirred at rt for 16h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo* to give cyclohexyl methanesulfonate.

A suspension of intermediate A (0.1g, 0.47mmol), cyclohexyl methanesulfonate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 50h. LC-MS indicated that the reaction was not complete so further cyclohexyl methanesulfonate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for 24h. Further cyclohexyl methanesulfonate (1eq) and potassium carbonate (1eq) was then added and the mixture stirred at 80°C for a further 24h. After cooling to rt, the mixture was filtered and the solid washed with dichloromethane. The filtrate was washed with H₂O. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title product. ¹H NMR (d₆-DMSO) δ 9.94 (s, 1H), 8.96 (s, 1H), 8.09 (s, 1H), 7.98 (s, 1H), 7.65 (s, 1H), 4.56-4.62 (m, 1H), 3.86 (s, 3H), 1.86-1.95 (m,


6H), 1.65-1.77 (m, 1H), 1.48-1.54 (m, 2H), 1.24-1.37 (m, 1H); LC-MS method B, (ES+) 298, RT = 8.61 min.

5 **Example 9:** *N*-(1-methyl-1H-pyrazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine



A suspension of intermediate A (0.1g, 0.47mmol), 4-chlorotetrahydro-2H-pyran (1eq) and
10 potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 18h. LC-MS indicated that
the reaction was not complete so further 4-chlorotetrahydro-2H-pyran (1eq) and potassium
carbonate (1eq) were added and the mixture stirred at 80°C for 24h. Further 4-
chlorotetrahydro-2H-pyran (2eq) and potassium carbonate (2eq) were again added and the
15 mixture stirred at 80°C for 72h. After cooling to rt, the mixture was treated with H₂O and
extracted with dichloromethane. The organic phase was collected and dried using a
hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep.
HPLC to give the title product. ¹H NMR (d₆-DMSO) δ 9.77 (s, 1H), 8.90 (s, 1H), 8.02 (s, 1H),
7.61 (s, 1H), 4.84 (s, 1H), 4.02 (dd, 2H), 3.84 (s, 3H), 3.58 (t, 2H), 2.20 (td, 2H), 1.90 (dd,
20 2H); LC-MS method B, (ES+) 300, RT = 6.36 min.

Example 10: *N*-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine




25 A solution of tert-butyl-3-hydroxypiperidine-1-carboxylate (0.35g, 1.74mmol) and
methanesulfonyl chloride (2eq) in pyridine (8mL) was stirred at rt for 16h. The mixture was
treated with H₂O and extracted with dichloromethane. The organic phase was collected and
dried using a hydrophobic frit then concentrated *in vacuo* to give tert-butyl-3-
((methylsulfonyl)oxy)piperidine-1-carboxylate.

A suspension of intermediate A (0.1g, 0.47mmol), tert-butyl-3-((methylsulfonyl)oxy)piperidine-1-carboxylate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so
5 further tert-butyl-3-((methylsulfonyl)oxy)piperidine-1-carboxylate (1eq) and potassium carbonate (1eq) were added and the mixture stirred at 80°C for 24h. Further tert-butyl-3-((methylsulfonyl)oxy)piperidine-1-carboxylate (2eq) and potassium carbonate (2eq) were then added and the mixture stirred at 80°C for 72h. After cooling to rt, the mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried
10 using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give tert-butyl-3-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate.

To a solution of tert-butyl-3-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate in dichloromethane (5mL) was added and excess
15 of trifluoroacetic acid. The mixture was stirred at rt for 2h and then diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The organic phase was collected, dried using a hydrophobic frit and then concentrated *in vacuo* to give the title product. ¹H NMR (CD₃OD) δ 8.88 (s, 1H), 8.05 (s, 1H), 7.97 (s, 1H), 7.73 (s, 1H), 5.16 (m, 1H), 3.91 (s, 3H), 2.19-2.33 (m, 4H), 2.04-2.08 (m, 2H), 1.89-1.96 (m, 2H);
20 LC-MS method B, (ES+) 299, RT = 4.18 min.


Example 11: *Rac-cis-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*
25



A solution of trans-2-methylcyclohexanol (0.35g, 3.07mmol) and methanesulfonyl chloride (2eq) in pyridine (8mL) was stirred at rt for 16h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried using a
30 hydrophobic frit then concentrated *in vacuo* to give trans-2-methylcyclohexyl methanesulfonate.

A suspension of intermediate A (0.1g, 0.47mmol), trans-2-methylcyclohexyl methanesulfonate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 50h. LC-MS indicated that the reaction was not complete so further trans-2-methylcyclohexyl methanesulfonate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for 24h. Further trans-2-methylcyclohexyl methanesulfonate (1eq) and potassium carbonate (1eq) was then added and the mixture stirred at 80°C for a further 24h. After cooling to rt, the mixture was filtered and the solid washed with dichloromethane. The filtrate was washed with H₂O. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title product. ¹H NMR (d₆-DMSO) δ 9.74 (s, 1H), 8.90 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 4.88 (s, 1H), 3.83 (s, 3H), 2.29 (m, 1H), 2.14-2.18 (m, 1H), 1.99 (m, 1H), 1.86 (m, 1H), 1.74-1.78 (m, 1H), 1.63-1.66 (m, 2H), 1.49 (m, 2H), 0.66 (d, 3H); LC-MS method B, (ES⁺) 312, RT = 9.50 min.


Example 12: *N*-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-*d*]pyrimidin-6-amine



A suspension of intermediate A (0.1g, 0.47mmol), tert-butyl-4-((methylsulfonyl)oxy)piperidine-1-carboxylate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 50h. LC-MS indicated that the reaction was not complete so further tert-butyl-4-((methylsulfonyl)oxy)piperidine-1-carboxylate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for 24h. Again, further tert-butyl-4-((methylsulfonyl)oxy)piperidine-1-carboxylate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for a further 24h. After cooling to rt, the mixture was filtered and the solid washed with dichloromethane. The filtrate was washed with H₂O. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give tert-butyl-4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-*d*]pyrimidin-1-yl)piperidine-1-carboxylate.

To a solution of tert-butyl-4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate in dichloromethane (5mL) was added an excess of trifluoroacetic acid and the mixture was stirred at rt for 2 h. The mixture was then diluted with dichloromethane then washed with saturated aqueous sodium bicarbonate solution. The organic phase was collected, dried using a hydrophobic frit and then concentrated *in vacuo* to give the title product. ¹H NMR (CD₃OD) δ 8.87 (s, 1H), 8.04 (s, 1H), 8.02 (s, 1H), 7.73 (s, 1H), 5.07-5.11 (m, 1H), 3.92 (s, 3H), 3.60-3.64 (m, 2H), 2.45-2.49 (m, 2H), 2.27-2.32 (m, 2H), 2.17-2.20 (m, 1H), 2.11-2.12 (m, 1H); LC-MS method B, (ES+) 299, RT = 4.15 min.

Example 13: *N*-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine




A solution of 3-methylcyclohexanol (0.25g, 2.19mmol) and methanesulfonyl chloride (2eq) in pyridine (8mL) was stirred at rt for 16h. The mixture was treated with H₂O and extracted with dichloromethane. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo* to give 3-methylcyclohexyl methanesulfonate.

A suspension of intermediate A (0.1g, 0.47mmol), 3-methylcyclohexanol methanesulfonate (1eq) and potassium carbonate (2eq) in DMF (3mL) was stirred at 80°C for 50h. LC-MS indicated that the reaction was not complete so further 3-methylcyclohexanol methanesulfonate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for 24h. Again, further 3-methylcyclohexanol methanesulfonate (1eq) and potassium carbonate (1eq) was added and the mixture stirred at 80°C for a further 24h. After cooling to rt, the mixture was filtered and the solid washed with dichloromethane. The filtrate was washed with H₂O. The organic phase was collected and dried using a hydrophobic frit then concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title compound. ¹H NMR (d₆-DMSO) δ 9.76 (s, 1H), 8.89 (s, 1H), 7.99 (s, 1H), 7.95 (s, 1H), 7.60 (s, 1H), 4.68 (s), 4.60 (s), 3.83 (s), 3.82 (s), 2.01-2.09 (m), 1.85-1.90 (m), 1.61-1.74 (m), 1.49-

1.53 (m), 1.29-1.34 (m), 1.07-1.09 (m), 0.96 (d), 0.91 (d); LC-MS method B, (ES+) 312, RT = 9.43 min.

5

Example 14: *N*-(1-Methyl-1*H*-pyrazol-4-yl)-1-(2-methylcyclopentyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-6-amine




10 A solution of 2-methylcyclopentanol (0.3g, 3.0mmol), triethylamine (2eq) and methanesulfonyl chloride (1.5eq) in dichloromethane (10mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 2-methylcyclopentyl methanesulfonate.

15

A suspension of intermediate A (50mg, 0.23mmol), potassium carbonate (2eq) and 2-methylcyclopentyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so further 2-methylcyclopentyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 20 80°C for 24h. Again, further 2-methylcyclopentyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) 25 δ 8.77 (s, 1H), 7.92 (s, 1H), 7.87 (s, 1H), 7.67 (s, 1H), 7.38 (s, 1H), 5.19-5.24 (m, 1H), 3.95 (s, 3H), 2.29-2.42 (m, 3H), 2.10-2.13 (m, 1H), 1.65-1.77 (m, 2H), 0.86-0.88 (m, 1H), 0.61 (d, 3H); LC-MS method B, (ES+) 298.1, RT = 8.83 min.


30 **Example 15:** *N*-(1-Methyl-1*H*-pyrazol-4-yl)-1-(3-methylcyclopentyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-6-amine



A solution of 3-methylcyclopentanol (0.3g, 3.0mmol), triethylamine (2eq) and methanesulfonyl chloride (1.5eq) in dichloromethane (10mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then
5 brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 3-methylcyclopentyl methanesulfonate.


A suspension of intermediate A (50mg, 0.23mmol), potassium carbonate (2eq) and 3-methylcyclopentyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-
10 MS indicated that the reaction was not complete so further 3-methylcyclopentyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to
15 give the title product as a 3:2 mixture of two isomers which were inseparable. Isomer 1 (60%): ¹H NMR (d₆-DMSO) δ 9.74 (s, 1H), 8.88 (s, 1H), 7.99-8.02 (m, 2H), 7.60 (s, 1H), 5.29 (s, 1H), 2.34-2.42 (m, 1H), 2.23-2.31 (m, 1H), 2.01-2.16 (m, 3H), 1.69-1.77 (m, 1H), 1.25-1.35 (m, 1H), 1.06 (d, 3H); Isomer 2 (40%): ¹H NMR (d₆-DMSO) δ 9.74 (s, 1H), 8.88 (s, 1H), 7.99-8.02 (m, 2H), 7.60 (s, 1H), 5.21 (s, 1H), 2.23-2.31 (m, 1H), 2.01-2.16 (m, 3H),
20 1.86-1.95 (m, 1H), 1.69-1.77 (m, 1H), 1.46-1.56 (m, 1H), 1.11 (d, 3H); LC-MS method B, (ES+) 298.0, RT = 8.87 min.

Example 16: 1-(Cyclohexylmethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-
25 d]pyrimidin-6-amine



A suspension of intermediate A (50mg, 0.23mmol), potassium carbonate (2eq) and cyclohexylmethylbromide (1eq) in DMF (2mL) was stirred at 80°C for 18h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) δ 8.75 (s, 1H), 8.02 (s, 1H), 7.82 (s, 1H), 7.76 (s, 1H), 4.19 (d, 2H), 3.95 (s, 3H), 2.65-2.78 (m, 4H), 2.03-2.09 (m, 1H), 1.73-1.76 (m, 2H), 1.62-1.65 (m, 2H), 1.11-1.27 (m, 2H), 1.03-1.10 (m, 2H); LC-MS method B, (ES+) 312.2, RT = 9.18 min.

Example 17: *1-(1-Cyclohexylethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*




To a solution of cyclohexane carboxaldehyde (0.40g, 3.6mmol) in THF (20mL) at 0°C was added methylmagnesium bromide (1.2eq of a 3M solution in diethyl ether) and the reaction stirred at rt for 2h. The reaction was then quenched with H₂O and extracted into EtOAc. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 1-cyclohexylethanol.

A solution of 1-cyclohexylethanol (0.43g, 3.36mol), triethylamine (2eq) and methanesulfonyl chloride (1.5eq) in dichloromethane (10mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 1-cyclohexylethyl methanesulfonate.

A suspension of intermediate A (50mg, 0.23mmol), potassium carbonate (2eq) and 1-cyclohexylethyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so further 1-cyclohexylethyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine.

The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) δ 8.77 (s, 1H), 7.93 (s, 1H), 7.86 (s, 1H), 7.67 (s, 1H), 4.58-4.61 (m, 1H), 3.95 (s, 3H), 1.93-1.96 (m, 2H), 1.76-1.79 (m, 2H), 1.65-1.68 (m, 2H), 1.56 (d, 3H), 1.11-1.20 (m, 3H), 0.84-0.91 (m, 2H); LC-MS method B, (ES+) 326.2, RT = 9.82 min.

Example 18: *1-(1-Cyclohexylpropyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*




To a solution of cyclohexane carboxaldehyde (0.40g, 3.6mmol) in THF (20mL) at 0°C was added ethylmagnesium bromide (1.2eq of a 3M solution in diethyl ether) and the reaction stirred at rt for 2h. The reaction was then quenched with H₂O and extracted into EtOAc. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 1-cyclohexylpropan-1-ol.

A solution of 1-cyclohexylpropan-1-ol (0.47g, 3.36mol), triethylamine (2eq) and methanesulfonyl chloride (1.5eq) in dichloromethane (10mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give 1-cyclohexylpropyl methanesulfonate.

A suspension of intermediate A (50mg, 0.23mmol), potassium carbonate (2eq) and 1-cyclohexylpropyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so further 1-cyclohexylethyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) δ 8.79 (s, 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.69 (s, 1H), 7.23 (s,

1H), 4.35-4.40 (m, 1H), 3.96 (s, 3H), 1.98-2.06 (m, 3H), 1.78-1.81 (m, 2H), 1.62-1.65 (m, 3H), 0.92-1.32 (m, 5H), 0.68 (t, 3H); LC-MS method B, (ES+) 340.2, RT = 10.42 min.

5 **Example 19:** *Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*




A solution of cis-3-methylcyclohexanol (0.40g, 3.57mmol) and methanesulfonyl chloride
10 (1.5eq) in dichloromethane (7mL) and pyridine (3mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give cis-3-methylcyclohexyl methanesulfonate.

15 A suspension of intermediate A (80mg, 0.37mmol), potassium carbonate (2eq) and cis-3-methylcyclohexyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so further cis-3-methylcyclohexyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O
20 and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) δ 8.78 (s, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.62 (s, 1H), 4.90-4.97 (m, 1H), 3.93 (s, 3H), 2.13-2.27 (m, 3H), 1.95-2.01 (m, 2H), 1.66-1.79 (m, 3H), 1.42-1.45 (m, 1H), 1.15 (d, 3H); LC-MS method B, (ES+) 312.2, RT = 9.44 min.

25


Example 20: *1-Cycloheptyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine*



A solution of cycloheptanol (0.34g, 3.57mmol) and methanesulfonyl chloride (1.5eq) in dichloromethane (7mL) and pyridine (3mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give cycloheptyl methanesulfonate.

A suspension of intermediate A (80mg, 0.37mmol), potassium carbonate (2eq) and cycloheptyl methanesulfonate (1eq) in DMF (2mL) was stirred at 80°C for 18h. LC-MS indicated that the reaction was not complete so cycloheptyl methanesulfonate (2eq) and potassium carbonate (2eq) were added and the reaction stirred at 80°C for 24h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give the title product. ¹H NMR (CDCl₃) δ 8.77 (s, 1H), 7.90 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 7.19 (s, 1H), 4.80-4.85 (m, 1H), 3.94 (s, 3H), 2.19-2.27 (m, 2H), 2.05-2.12 (m, 2H), 1.87-1.94 (m, 2H), 1.55-1.77 (m, 5H), 1.26-1.28 (m, 1H); LC-MS method B, (ES+) 312.1, RT = 9.26 min.

Example 21: 2-methoxy-1-(3-(((6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone




A solution of N-Boc-piperidine-3-methanol (1.0g, 4.65mmol), triethylamine (2eq) and methanesulfonyl chloride (1.5eq) in dichloromethane (7mL) was stirred at rt for 18h. The resultant mixture was then diluted with dichloromethane and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo* to give tert-butyl 3-(((methanesulfonyl)oxy)methyl)piperidine-1-carboxylate.






A suspension of intermediate A (200mg, 0.93mmol), potassium carbonate (2eq) and tert-butyl 3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate (1eq) in DMF (2mL) was stirred at 80°C for 18h. After cooling to rt, the mixture was diluted with EtOAc and washed with H₂O and then brine. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by column chromatography (petroleum ether: EtOAc) to give tert-butyl 3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate.






To a solution of tert-butyl 3-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (5mL) was added an excess of trifluoroacetic acid and the mixture was stirred at rt for 2 h. The mixture was then diluted with dichloromethane then washed with saturated aqueous sodium bicarbonate solution. The organic phase was collected, dried (MgSO₄) and then concentrated *in vacuo* to give N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine.







To a solution of N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (40mg, 0.13mmol) and triethylamine (2eq) in dichloromethane (5mL) was added 2-methoxyacetyl chloride (1eq) and the reaction stirred at rt for 30min. The mixture was then diluted with dichloromethane and washed with water. The organic phase was collected, dried (MgSO₄) and concentrated *in vacuo*. The resultant residue was purified by prep. HPLC to give the title product. ¹H NMR (d₆-DMSO, run at 70°C) δ 9.49 (s, 1H), 8.88 (s, 1H), 8.00 (s, 1H), 7.95 (s, 1H), 7.60 (s, 1H), 4.23 (d, 2H), 3.94-3.97 (m, 2H), 3.84 (s, 3H), 3.76-3.79 (m, 1H), 3.19-3.21 (m, 2H), 3.07 (s, 3H), 2.91-2.95 (m, 1H), 2.14-2.17 (m, 1H), 1.67-1.74 (m, 2H), 1.25-1.41(m, 2H); LC-MS method B, (ES+) 385.1, RT = 6.21 min.







The following compounds were synthesized by procedures analogous to those described above:








Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 C ₁₇ H ₂₂ N ₈ O	N-(4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)acetamide	22	C	355.4	6.02	>85







Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>C12H26N8O3S</chem>	1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one	23	C	447.5	6.23	>95
 <chem>C17H26N9O</chem>	3-(4-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile	24	C	366.4	6.16	>95
 <chem>C17H26N9O</chem>	3-(3-(6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile	25	C	366.4	6.56	>85
 <chem>C18H26N9O</chem>	3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-oxopropanenitrile	26	C	380.4	6.43	>90
 <chem>C19H26N8O2</chem>	3-methoxy-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propan-1-one	27	C	399.5	6.46	>95






Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>C_{21}H_{28}N_8O_2</chem>	(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone	28	C	425.5	6.59	>95
 <chem>C_{19}H_{27}N_9O</chem>	2-(dimethylamino)-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone	29	C	398.5	4.45	>95
 <chem>C_{16}H_{22}N_8</chem>	N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	30	C	327.4	4.51	>90
 <chem>C_{17}H_{24}N_8O_2S</chem>	1-((1-(ethylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	31	C	405.5	7.14	>95
 <chem>C_{18}H_{26}N_8O_2S</chem>	1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	32	C	419.5	7.49	>95






Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>C18H24N8O2S</chem>	1-((1-(cyclopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	33	C	417.5	7.22	>95
 <chem>C17H24N8O2S</chem>	N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(1-(methylsulfonyl)piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	34	C	405.5	6.94	>95
 <chem>C18H26N8O</chem>	1-((1-(2-methoxyethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	35	C	371.5	4.26	>90
 <chem>C18H24N8O2</chem>	ethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate	36	C	385.4	7.57	>95
 <chem>C18H26N8S</chem>	N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylthio)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	37	C	387.5	4.51	>90
 <chem>C17H22N8O2</chem>	methyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate	38	C	371.4	7.14	>95


Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>C17H22N6O3S</chem>	2-(4-((1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-1H-pyrazol-1-yl)ethanol	39	C	421.5	6.1	>90
 <chem>C14H18N8</chem>	N-(1-methyl-1H-pyrazol-4-yl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	40	C	299.3	3.88	>95
 <chem>C18H23N9</chem>	3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile	41	C	366.4	4.01	>95
 <chem>C16H22N8O2S</chem>	1-((1-(ethylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	42	C	391.5	6.67	>95
 <chem>C17H22N8O2S</chem>	1-((1-(cyclopropylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	43	C	403.5	6.92	>95
 <chem>C18H23FN8O2</chem>	2-fluoroethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate	44	C	403.4	7.34	>95

Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 C ₁₉ H ₂₆ N ₈ O ₃	2-methoxyethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate	45	C	415.5	7.09	>95
 C ₁₈ H ₂₆ N ₈ O ₂ S	N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	46	C	419.5	4.1	>95
 C ₁₇ H ₁₉ F ₃ N ₈ O	2,2,2-trifluoro-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone	47	C	409.4	7.97	>95
 C ₁₅ H ₂₀ N ₈ O ₂ S	N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	48	C	377.4	6.29	>95
 C ₁₆ H ₁₉ N ₉	3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidin-1-yl)propanenitrile	49	C	338.4	6.14	>95
 C ₁₇ H ₂₂ N ₇ O	Rac-trans-2-(4-((1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-1H-pyrazol-1-yl)ethanol	50	C	342.4	7.9	>95
 C ₁₈ H ₂₅ N ₉ O	N-ethyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide	51	C	384.5	6.52	>95

Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>C19H25N9O</chem>	N-cyclopropyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide	52	C	396.5	6.57	>95
 <chem>C17H21N9</chem>	3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)propanenitrile	53	C	352.4	4.11	>95
 <chem>C17H21N9</chem>	2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile	54	C	352.4	6.16	>95
 <chem>C17H24N8</chem>	1-((1-ethylpiperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	55	C	341.4	4.18	>95
 <chem>C20H26F2N8OS</chem>	1-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylthio)propan-1-one	56	C	465.5	7.72	>95
 <chem>C19H23F2N9</chem>	3-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile	57	C	416.4	4.53	>95

Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 C ₁₉ H ₂₈ N ₈ O	1-((1-(3-methoxypropyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	58	C	385.5	4.39	>95
 C ₂₀ H ₂₈ F ₂ N ₈ O ₅ S	1-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one	59	C	497.5	6.67	>95
 C ₁₈ H ₂₁ F ₂ N ₉	2-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile	60	C	402.4	6.96	>90
 C ₁₉ H ₂₈ F ₂ N ₈ O ₂ S	N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	61	C	469.5	8.35	>95
 C ₁₉ H ₂₈ N ₈ O ₂ S	N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(3-(methylsulfonyl)propyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	62	C	433.5	4.12	>95

Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 <chem>CC(C)CNC(=O)CN1CCN(CC1Cc2nc3nc(Nc4ccn(C)c4)cnc3n2)C5CCNCC5</chem> $C_{20}H_{29}N_9O$	N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide	63	C	412.5	4.46	>95
 <chem>CNC(=O)CN1CCN(CC1Cc2nc3nc(Nc4ccn(C)c4)cnc3n2)C5CCNCC5</chem> $C_{19}H_{25}N_9O$	N-methyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide	64	C	384.5	4.16	>95
 <chem>CN(C)C(=O)N1CCN(CC1Cc2nc3nc(Nc4ccn(C)c4)cnc3n2)C5CCNCC5</chem> $C_{18}H_{25}N_9O$	N,N-dimethyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide	65	C	384.5	6.7	>95
 <chem>OCCN1CCN(CC1Cc2nc3nc(Nc4ccn(C)c4)cnc3n2)C5CCNCC5</chem> $C_{17}H_{24}N_8O$	2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanol	66	C	357.4	4.17	>95
 <chem>FC(F)CCN1CCN(CC1Cc2nc3nc(Nc4ccn(C)c4)cnc3n2)C5CCNCC5</chem> $C_{17}H_{22}F_2N_8$	1-((1-(2,2-difluoroethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine	67	C	377.4	4.39	>95

Structure	Name	Example number	LCMS Method	ES+	RT (mins)	Purity (%)
 C ₁₂ H ₂₇ N ₉ O	N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)acetamide	68	C	398.5	4.4	>80

5 Biology Assays

Determination of the effect of the compounds according to the invention on JAK

The compounds of the present invention as described in the previous examples were tested in a Kinobeads™ assay as described for ZAP-70 (WO-A 2007/137867). Briefly, test compounds (at various concentrations) and the affinity matrix with the immobilized aminopyrido-pyrimidine ligand 24 were added to cell lysate aliquots and allowed to bind to the proteins in the lysate sample. After the incubation time the beads with captured proteins were separated from the lysate. Bound proteins were then eluted and the presence of JAK2 and JAK3 was detected and quantified using specific antibodies in a dot blot procedure and the Odyssey infrared detection system. Dose response curves for individual kinases were generated and IC₅₀ values calculated. Kinobeads™ assays for ZAP-70 (WO-A 2007/137867) and for kinase selectivity profiling (WO-A 2006/134056) have been previously described.

20 Protocols

Washing of affinity matrix

The affinity matrix was washed two times with 15mL of 1x DP buffer containing 0.2% NP40 (IGEPAL® CA-630, Sigma, #I3021) and then resuspended in 1xDP buffer containing 0.2% NP40 (3% beads slurry).

5xDP buffer: 250mM Tris-HCl pH 7.4, 25% Glycerol, 7.5mM MgCl₂, 750mM NaCl, 5mM Na₃VO₄; filter the 5xDP buffer through a 0.22µm filter and store in aliquots at -80°C. The 5xDP buffer is diluted with H₂O to 1xDP buffer containing 1mM DTT and 25mM NaF.

Preparation of test compounds

Stock solutions of test compounds were prepared in DMSO. In a 96 well plate 30µL solution of diluted test compounds at 5mM in DMSO were prepared. Starting with this solution a 1:3 dilution series (9 steps) was prepared. For control experiments (no test compound) a buffer containing 2% DMSO was used.

Cell culture and preparation of cell lysates

Molt4 cells (ATCC catalogue number CRL-1582) and Ramos cells (ATCC catalogue number CRL-1596) were grown in 1L Spinner flasks (Integra Biosciences, #182101) in suspension in RPMI 1640 medium (Invitrogen, #21875-034) supplemented with 10% Fetal Bovine Serum (Invitrogen) at a density between 0.15×10^6 and 1.2×10^6 cells/mL. Cells were harvested by centrifugation, washed once with 1 x PBS buffer (Invitrogen, #14190-094) and cell pellets were frozen in liquid nitrogen and subsequently stored at -80°C. Cells were homogenized in a Potter S homogenizer in lysis buffer: 50mM Tris-HCl, 0.8% NP40, 5% glycerol, 150mM NaCl, 1.5mM MgCl₂, 25 mM NaF, 1mM sodium vanadate, 1mM DTT, pH 7.5. One complete EDTA-free tablet (protease inhibitor cocktail, Roche Diagnostics, 1873580) per 25mL buffer was added. The material was dounced 10 times using a mechanized POTTER S, transferred to 50mL falcon tubes, incubated for 30 minutes on ice and spun down for 10 minutes at 20,000 g at 4°C (10,000 rpm in Sorvall SLA600, precooled). The supernatant was transferred to an ultracentrifuge (UZ)-polycarbonate tube (Beckmann, 355654) and spun for 1hour at 100.000g at 4°C (33.500 rpm in Ti50.2, precooled). The supernatant was transferred again to a fresh 50mL falcon tube, the protein concentration was determined by a Bradford assay (BioRad) and samples containing 50mg of protein per aliquot were prepared. The samples were immediately used for experiments or frozen in liquid nitrogen and stored frozen at -80°C.

Dilution of cell lysate

Cell lysate (approximately 50mg protein per plate) was thawed in a water bath at room temperature and then stored on ice. To the thawed cell lysate 1xDP 0.8% NP40 buffer containing protease inhibitors (1 tablet for 25mL buffer; EDTA-free protease inhibitor cocktail; Roche Diagnostics 1873580) was added in order to reach a final protein concentration of 10mg/mL total protein. The diluted cell lysate was stored on ice. Mixed

Molt4/Ramos lysate was prepared by combining one volume of Molt4 lysate and two volumes of Ramos lysate (ratio 1:2).

Incubation of lysate with test compound and affinity matrix

- 5 To a 96 well filter plate (Multiscreen HTS, BV Filter Plates, Millipore #MSBVN1250) were added per well: 100µL affinity matrix (3% beads slurry), 3µL of compound solution, and 50µL of diluted lysate. Plates were sealed and incubated for 3 hours in a cold room on a plate shaker (Heidolph tiramax 1000) at 750rpm. Afterwards the plate was washed 3 times with 230µL washing buffer (1xDP 0.4% NP40). The filter plate was placed on top of a collection
10 plate (Greiner bio-one, PP-microplate 96 well V-shape, 65120) and the beads were then eluted with 20µL of sample buffer (100 mM Tris, pH 7.4, 4% SDS, 0.00025% bromophenol blue, 20% glycerol, 50 mM DTT). The eluate was frozen quickly at -80°C and stored at -20°C.

15 Detection and quantification of eluted kinases

- The kinases in the eluates were detected and quantified by spotting on nitrocellulose membranes and using a first antibody directed against the kinase of interest and a fluorescently labelled secondary antibody (anti-rabbit IRDyeTM antibody 800 (Licor, # 926-32211). The Odyssey Infrared Imaging system from LI-COR Biosciences (Lincoln,
20 Nebraska, USA) was operated according to instructions provided by the manufacturer (Schutz-Geschwendener *et al.*, 2004. Quantitative, two-color Western blot detection with infrared fluorescence. Published May 2004 by LI-COR Biosciences, www.licor.com).

- After spotting of the eluates the nitrocellulose membrane (BioTrace NT; PALL, #BTNT30R)
25 was first blocked by incubation with Odyssey blocking buffer (LICOR, 927-40000) for 1 hour at room temperature. Blocked membranes were then incubated for 16 hours at the temperature shown in table 4 with the first antibody diluted in Odyssey blocking buffer (LICOR #927-40000). Afterwards the membrane was washed twice for 10 minutes with PBS buffer containing 0.2% Tween 20 at room temperature. The membrane was then incubated
30 for 60 minutes at room temperature with the detection antibody (anti-rabbit IRDyeTM antibody 800, Licor, # 926-32211) diluted in Odyssey blocking buffer (LICOR #927-40000). Afterwards the membrane was washed twice for 10 minutes each with 1 x PBS buffer containing 0.2% Tween 20 at room temperature. Then the membrane was rinsed once with PBS buffer to remove residual Tween 20. The membrane was kept in PBS buffer at 4°C and

then scanned with the Odyssey instrument. Fluorescence signals were recorded and analysed according to the instructions of the manufacturer.

Table 5: Sources and dilutions of antibodies

5

Target kinase	Primary antibody (dilution)	Temp of Primary incubation	Secondary antibody (dilution)
Jak2	Cell signaling #3230 (1:100)	Room temperature	Licor anti-rabbit 800 (1:15000)
Jak3	Cell signaling #3775 (1:100)	4°C	Licor anti-rabbit 800 (1:5000)

Results

10 **Table 6:** Inhibition values (IC_{50} in μM) as determined in the Kinobeads™ assay (Activity level: $A < 0.1\mu M \leq B < 1\mu M \leq C \leq 10\mu M < D$).


Example	JAK2	JAK3
	IC_{50} (μM)	IC_{50} (μM)
1	C	A
2	C	B
3	C	B
4	C	A
5	C	B
6	C	A
7	C	A
8	D	B
9	D	B
10	D	C
11	C	B
12	D	C
13	D	B
14	D	B
15	C	B
16	C	A
17	D	B
18	D	B
19	C	A
20	C	A
21	D	A
22	C	B

23	C	A
24	C	B
25	D	B
26	C	A
27	C	B
28	D	B
29	D	B
30	D	B
31	C	A
32	C	A
33	C	A
34	C	B
35	D	A
36	D	B
37	D	A
38	D	B
39	C	A
40	C	B
41	C	A
42	D	B
43	D	B
44	D	B
45	D	B
46	C	A
47	C	B
48	D	B
49	D	B
50	C	A
51	C	A
52	C	A
53	C	A
54	C	A
55	C	A
56	D	B
57	D	A
58	D	B
59	D	B
60	C	B
61	C	A
62	C	A
63	D	B
64	C	A
65	C	A
66	C	A
67	C	A
68	D	B

Patent Claims

1. A compound of formula (I)

5



or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein

- 10 R^1 is H; $C(O)OR^3$; $C(O)R^3$; $C(O)N(R^3R^{3a})$; $S(O)_2N(R^3R^{3a})$; $S(O)N(R^3R^{3a})$; $S(O)_2R^3$; $S(O)R^3$; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; or C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more R^4 , which are the same or different;

- 15 R^{1a} , R^{1b} are independently selected from the group consisting of H; halogen, CN, OR^{1c} ; C_{1-6} alkyl; wherein C_{1-6} alkyl; is optionally substituted with one or more halogen, which are the same or different;

- 20 R^{1c} is H or C_{1-6} alkyl; wherein C_{1-6} alkyl; is optionally substituted with one or more halogen, which are the same or different;

- 25 R^3 , R^{3a} are independently selected from the group consisting of H; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more R^4 , which are the same or different;

- 30 R^4 is halogen; CN; $C(O)OR^5$; OR^5 ; $C(O)R^5$; $C(O)N(R^5R^{5a})$; $S(O)_2N(R^5R^{5a})$; $S(O)N(R^5R^{5a})$; $S(O)_2R^5$; $S(O)R^5$; $N(R^5)S(O)_2N(R^{5a}R^{5b})$; $N(R^5)S(O)N(R^{5a}R^{5b})$; SR^5 ; $N(R^5R^{5a})$; NO_2 ; $OC(O)R^5$; $N(R^5)C(O)R^{5a}$; $N(R^5)S(O)_2R^{5a}$; $N(R^5)S(O)R^{5a}$; $N(R^5)C(O)N(R^{5a}R^{5b})$; $N(R^5)C(O)OR^{5a}$; $OC(O)N(R^5R^{5a})$; or T^1 ;

30

R^5 , R^{5a} , R^{5b} are independently selected from the group consisting of H; T^1 ; C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl, wherein C_{1-6} alkyl; C_{2-6} alkenyl; and C_{2-6} alkynyl are optionally substituted with one or more halogen, which are the same or different;

5 R^2 is T^2 ; or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more R^6 , which are the same or different;

10 R^6 is T^2 ; halogen; CN; $C(O)OR^7$; OR^7 ; $C(O)R^7$; $C(O)N(R^7R^{7a})$; $S(O)_2N(R^7R^{7a})$; $S(O)N(R^7R^{7a})$; $S(O)_2R^7$; $S(O)R^7$; $N(R^7)S(O)_2N(R^{7a}R^{7b})$; $N(R^7)S(O)N(R^{7a}R^{7b})$; SR^7 ; $N(R^7R^{7a})$; NO_2 ; $OC(O)R^7$; $N(R^7)C(O)R^{7a}$; $N(R^7)S(O)_2R^{7a}$; $N(R^7)S(O)R^{7a}$; $N(R^7)C(O)N(R^{7a}R^{7b})$; $N(R^7)C(O)OR^{7a}$; or $OC(O)N(R^7R^{7a})$;

15 R^7 , R^{7a} , R^{7b} are independently selected from the group consisting of H; T^2 ; or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^8 , which are the same or different;

T^1 is C_{3-7} cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T^1 is optionally substituted with one or more R^{8a} , which are the same or different;

20 R^{8a} is C_{1-6} alkyl or halogen;

T^2 is C_{3-7} cycloalkyl; 4 to 7 membered saturated heterocyclyl; 1,2,3,4-tetrahydroquinoline 1,2,3,4-tetrahydroisoquinoline or indoline, wherein T^2 is optionally substituted with one or more R^9 , which are the same or different;

25 R^9 is halogen; CN; $C(O)OR^{10}$; OR^{10} ; oxo (=O); $C(O)R^{10}$; $C(O)N(R^{10}R^{10a})$; $S(O)_2N(R^{10}R^{10a})$; $S(O)N(R^{10}R^{10a})$; $S(O)_2R^{10}$; $S(O)R^{10}$; $N(R^{10})S(O)_2N(R^{10a}R^{10b})$; $N(R^{10})S(O)N(R^{10a}R^{10b})$; SR^{10} ; $N(R^{10}R^{10a})$; NO_2 ; $OC(O)R^{10}$; $N(R^{10})C(O)R^{10a}$; $N(R^{10})S(O)_2R^{10a}$; $N(R^{10})S(O)R^{10a}$; $N(R^{10})C(O)N(R^{10a}R^{10b})$; $N(R^{10})C(O)OR^{10a}$; $OC(O)N(R^{10}R^{10a})$; T^3 ; C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^{11} , which are the same or different;

30

R^{10} , R^{10a} , R^{10b} are independently selected from the group consisting of H; C_{1-4} alkyl; or T^3 wherein C_{1-4} alkyl is optionally substituted with one or more R^{12} , which are the same or different;

R^8 , R^{11} , R^{12} are independently selected from the group consisting of halogen; CN; $C(O)OR^{13}$; OR^{13} ; $C(O)R^{13}$; $C(O)N(R^{13}R^{13a})$; $S(O)_2N(R^{13}R^{13a})$; $S(O)N(R^{13}R^{13a})$; $S(O)_2R^{13}$; $S(O)R^{13}$; $N(R^{13})S(O)_2N(R^{13a}R^{13b})$; $N(R^{13})S(O)N(R^{13a}R^{13b})$; SR^{13} ; $N(R^{13}R^{13a})$; NO_2 ; $OC(O)R^{13}$; $N(R^{13})C(O)R^{13a}$; $N(R^{13})S(O)_2R^{13a}$; $N(R^{13})S(O)R^{13a}$; $N(R^{13})C(O)N(R^{13a}R^{13b})$; $N(R^{13})C(O)OR^{13a}$; $OC(O)N(R^{13}R^{13a})$ and T^3 ;

T^3 is C_{3-7} cycloalkyl; phenyl; or 4 to 7 membered heterocyclyl, wherein T^3 is optionally substituted with one or more R^{14} , which are the same or different;

R^{13} , R^{13a} , R^{13b} are independently selected from the group consisting of H; and C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more halogen, which are the same or different;

R^{14} is halogen, CN, OR^{15} ; or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different;

R^{15} is H; or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more halogen, which are the same or different.

2. A compound of claim 1, wherein R^1 is C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different.

3. A compound of claim 1 or 2, wherein R^{1a} , R^{1b} are H.

4. A compound of any of claims 1 to 3, wherein R^2 is T^2 ; or C_{1-6} alkyl substituted with at least 1 R^6 .

5. A compound of any of claims 1 to 4, wherein R^2 is T^2 ; CH_2-T^2 ; $CH(CH_3)-T^2$; $CH(CH_2CH_3)-T^2$; $C(CH_3)_2-T^2$; $CH(CH_2CH(CH_3)_2)-T^2$; or $CH_2CH_2T^2$.

6. A compound of any of claims 1 to 4, wherein R^2 is C_{1-6} alkyl substituted with at least 1 R^6 , provided that R^6 is other than T^2 .
7. A compound of any of claims 1 to 5, wherein T^2 is azetidine; piperidine; pyrrolidine; tetrahydropyran; cycloheptyl; cyclohexyl; or cyclopentyl and wherein T^2 is unsubstituted or substituted with one or more R^9 , which are the same or different.
8. A compound of any of claims 1 to 5 and 7, wherein R^9 is $N(R^{10})C(O)R^{10a}$; $C(O)OR^{10}$; $C(O)N(R^{10})R^{10a}$; $N(R^{10})S(O)_2R^{10a}$; $C(O)R^{10}$; $S(O)_2R^{10}$; or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted with one or more R^{11} , which are the same or different.
9. A compound of any of claims 1 to 4 and 6, wherein R^6 is $N(R^{10})S(O)_2R^{10a}$; $C(O)R^{10}$; or $S(O)_2R^{10}$.
10. A compound of claim 1 selected from the group consisting of
 - N-(1-Methyl-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - N-(3-(6-(1-methyl-1H-pyrazol-4-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)methanesulfonamide;
 - N-(1-methyl-1H-pyrazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - N-(1-methyl-1H-pyrazol-4-yl)-1-((1-methylpiperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - 1-cyclohexyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
 - N-(1-methyl-1H-pyrazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

- N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- Rac-cis-N-(1-methyl-1H-pyrazol-4-yl)-1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 5 N-(1-methyl-1H-pyrazol-4-yl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- N-(1-Methyl-1H-pyrazol-4-yl)-1-(2-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 10 N-(1-Methyl-1H-pyrazol-4-yl)-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-(Cyclohexylmethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 15 1-(1-Cyclohexylethyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-(1-Cyclohexylpropyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- Rac-trans-N-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 20 1-Cycloheptyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 2-methoxy-1-(3-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- N-(4-(6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)acetamide;
- 25 1-(3-(((6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one;
- 3-(4-(6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile;
- 30 3-(3-(6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile;
- 3-(3-(((6-(((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-oxopropanenitrile;

- 3-methoxy-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propan-1-one;
- (3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone;
- 5 2-(dimethylamino)-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(ethylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 10 1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(cyclopropylsulfonyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 15 N-(1-methyl-1H-pyrazol-4-yl)-1-(2-(1-(methylsulfonyl)piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(2-methoxyethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- ethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 20 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylthio)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- methyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 25 2-(4-((1-((1-(methylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-1H-pyrazol-1-yl)ethanol;
- N-(1-methyl-1H-pyrazol-4-yl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile;
- 30 1-((1-(ethylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 1-((1-(cyclopropylsulfonyl)pyrrolidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

- 2-fluoroethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 2-methoxyethyl 3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate;
- 5 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 2,2,2-trifluoro-1-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanone;
- 10 N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidin-1-yl)propanenitrile;
- Rac-trans-2-(4-((1-(2-methylcyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-1H-pyrazol-1-yl)ethanol;
- 15 N-ethyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;
- N-cyclopropyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;
- 3-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)propanenitrile;
- 20 2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile;
- 1-((1-ethylpiperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 25 1-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylthio)propan-1-one;
- 3-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)propanenitrile;
- 1-((1-(3-methoxypropyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
- 30 1-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)-3-(methylsulfonyl)propan-1-one;
- 2-(3-((6-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetonitrile;

N-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-1-((1-(isopropylsulfonyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

N-(1-methyl-1H-pyrazol-4-yl)-1-((1-(3-(methylsulfonyl)propyl)piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

5 N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide;

N-methyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)acetamide;

10 N,N-dimethyl-3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxamide;

2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidin-1-yl)ethanol;

1-((1-(2,2-difluoroethyl)piperidin-3-yl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; and

15 N-isopropyl-2-(3-((6-((1-methyl-1H-pyrazol-4-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidin-1-yl)acetamide.

11. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof of any claims 1 to 10 together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.

12. A compound or a pharmaceutically acceptable salt thereof of any claims 1 to 10 for use as a medicament.


13. A compound or a pharmaceutically acceptable salt thereof of any claims 1 to 10 for use in a method of treating or preventing a disease or disorder associated with JAK.

14. A compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 10 for use in a method of treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.

15. A method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of diseases and disorders associated with JAK, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to any of

16. A method for the preparation of a compound of any of claims 1 to 10 comprising the step of


reacting a compound of formula (II)




wherein R¹, R^{1a}, R^{1b} have the meaning as indicated in any of claims 1 to 10, with a compound of formula R²-X, wherein R² has the meaning as indicated in any of claims 1 to 10 and X is a suitable leaving group to yield a compound of formula (I).

17. A method for the preparation of a compound of any of claims 1 to 10 comprising the step of

reacting a compound of formula (III)



wherein R² has the meaning as indicated in any of claims 1 to 10, with a compound of formula (IV)



wherein R^1 , R^{1a} , R^{1b} have the meaning as indicated in any of claims 1 to 10 to yield a compound of formula (I).

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2011/056158

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D487/04 A61K31/519 A61P35/00 A61P29/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/094602 A2 (BIOGEN IDEC INC [US]; KASIBHATLA SRINIVAS RAO [US]; HONG KEVIN [US]; Z) 7 August 2008 (2008-08-07) paragraph [0061]; claims 1, 49-55; example 401 -----	1-17
A	WO 2006/074985 A1 (JANSSEN PHARMACEUTICA NV [BE]; FREYNE EDDY JEAN EDGARD [BE]; LACRAMPE) 20 July 2006 (2006-07-20) page 48, col. no. 16 claims 1, 7-10 -----	1-17
A	US 2009/203688 A1 (GAUL CHRISTOPH [CH] ET AL) 13 August 2009 (2009-08-13) claims 1, 8-9; examples 247, 253 -----	1-17

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 May 2011

Date of mailing of the international search report

31/05/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV Rijswijk

Tel. (+31-70) 340-2040,

Fax: (+31-70) 340-3016

Authorized officer

Sotoca Usina, E

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/056158

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008094602 A2	07-08-2008	AU 2008211108 A1	07-08-2008
		AU 2008211172 A1	07-08-2008
		CA 2676658 A1	07-08-2008
		CA 2676665 A1	07-08-2008
		EP 2108019 A2	14-10-2009
		EP 2108020 A2	14-10-2009
		JP 2010516812 T	20-05-2010
		JP 2010532312 T	07-10-2010
		US 2010190787 A1	29-07-2010
		US 2010249067 A1	30-09-2010
		WO 2008094575 A2	07-08-2008
WO 2006074985 A1	20-07-2006	AU 2006205851 A1	20-07-2006
		CA 2594425 A1	20-07-2006
		EP 1846408 A1	24-10-2007
		JP 2008526920 T	24-07-2008
		US 2008070914 A1	20-03-2008
US 2009203688 A1	13-08-2009	AR 070558 A1	21-04-2010
		AU 2009211338 A1	13-08-2009
		CA 2714177 A1	13-08-2009
		CN 101981036 A	23-02-2011
		EC SP100463 A	30-10-2010
		EP 2247591 A1	10-11-2010
		WO 2009098236 A1	13-08-2009
		KR 20100119786 A	10-11-2010
		PA 8815201 A1	17-09-2009
		PE 14852009 A1	26-10-2009
		SM AP201000104 A	12-11-2010
		UY 31631 A1	30-09-2009